In a report released today, Srikripa Devarakonda from Truist Financial reiterated a Hold rating on Incyte (INCY – Research Report), with a ...

Wells Fargo analyst Derek Archila maintained a Hold rating on Incyte (INCY – Research Report) yesterday and set a price target of $58.00. The ...

Shares of Incyte Corp. INCY slid 8.62% to $62.01 Monday, on what proved to be an all-around positive trading session for the ...

After hours: March 17 at 7:51:31 PM EDT Loading Chart for INCY ...

A month has gone by since the last earnings report for Incyte (INCY). Shares have added about 2.6% in that time frame, outperforming the S&P 500. Will the recent positive trend continue leading up ...

In the preceding three months, 6 analysts have released ratings for Incyte INCY, presenting a wide array of perspectives from bullish to bearish. The following table encapsulates their recent ...

The deal between Incyte and Genesis has a potential value of more than $900 million. Incyte Corp. is making a big bet on artificial intelligence with a new drug discovery partnership potentially ...

Incyte is sticking to its strategy this year of finding “early-stage, exotic stuff”—paying Genesis Therapeutics $30 million upfront to use the biotech’s artificial intelligence platform to ...

Incyte and Genesis will leverage Genesis’ GEMS artificial intelligence (AI) platform to unlock the discovery of breakthrough small molecule therapeutics against Incyte-selected targets Incyte ...